PharVision Advisers »

Genes shares owned by PharVision Advisers

Quarter-by-quarter ownership of Genes (GCO) shares owned by PharVision Advisers from 13F filings

Historical chart of PharVision Advisers investment in Genes

Tip: Access up to 7 years of quarterly data

All positions including Genes held by PharVision Advisers consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Genes by PharVision Advisers

Quarter filed Position value Share count Share price at filing
2025-09-30 $340k 12k 28.99

More positions owned by PharVision Advisers

Wayfair Cl A (W)
ExlService Holdings (EXLS)
Up Fintech Hldg Sponsored Ads (TIGR)
Array Technologies Com Shs (ARRY)
Sprouts Fmrs Mkt (SFM)
Corporacion Amer Arpts S A (CAAP)
Vertiv Holdings Com Cl A (VRT)
Zevra Therapeutics Com New (ZVRA)
Bowhead Specialty Hldgs Com Shs (BOW)
Lexinfintech Hldgs Adr (LX)
Euronet Worldwide (EEFT)
Rigel Pharmaceuticals (RIGL)
Masimo Corporation (MASI)
LSB Industries (LXU)
Bright Horizons Fam Sol In D (BFAM)

View all positions for PharVision Advisers

Top funds holding Genes

Pzena Investment Management
Fund 1 Investments
BlackRock
Vanguard Group
Dimensional Fund Advisors
Acadian Asset Management
Morgan Stanley
Nomura Holdings
D. E. Shaw & Co
Charles Schwab Investment Management
Arrowstreet Capital, Limited Partnership
State Street Corporation
Geode Capital Management
ING Groep
Healthcare Of Ontario Pension Plan Trust Fund

View all funds holding Genes